Pharmaceutical Companies

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

Through this acquisition, Mirum gains worldwide rights to brelovitug, a monoclonal antibody that has advanced to Phase III clinical development.

The local production of dydrogesterone represents not only an important milestone for Mubadala Bio and Bioventure Healthcare but also a timely contribution to supporting women’s health throughout the country.

The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.

Dr. Basson joins Variant Bio with more than 25 years of leadership experience spanning academic medicine, global pharmaceutical development, and biotechnology sectors.

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.

The plant is scheduled to begin operations by 2029 and will focus on producing cutting-edge treatments for metabolic conditions, particularly obesity medications.

The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.

The transaction marks the end of Pfizer’s involvement with ViiV Healthcare, as the American pharmaceutical giant sells its entire 11.7% stake in the company.

Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.